Literature DB >> 16786820

Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: A preliminary report.

Tony A Cohn1, Gary Remington, Robert B Zipursky, Azar Azad, Philip Connolly, Thomas M S Wolever.   

Abstract

OBJECTIVE: To compare the insulin sensitivity and adiponectin levels of medication-free patients suffering from schizophrenia or schizoaffective disorder with that of matched healthy volunteers.
METHOD: We evaluated 9 nondiabetic patients aged 26.6 years (median 26 years, range 17 to 41 years) and matched volunteers, using the frequently sampled intravenous glucose tolerance test, minimal model analysis, and fasting adiponectin levels.
RESULTS: The mean insulin sensitivity index of the patients was 42% lower than that of the healthy volunteers (P = 0.026), with inadequate compensation in insulin secretion. Patients with schizophrenia tended to have reduced adiponectin levels (P = 0.055).
CONCLUSIONS: By direct measurement, this study provides evidence of insulin resistance and susceptibility to type 2 diabetes in patients with schizophrenia who are free of antipsychotic drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16786820     DOI: 10.1177/070674370605100608

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  24 in total

Review 1.  Management of antipsychotic-related weight gain.

Authors:  Lawrence Maayan; Christoph U Correll
Journal:  Expert Rev Neurother       Date:  2010-07       Impact factor: 4.618

2.  Schizophrenia as a systemic disease.

Authors:  Brian Kirkpatrick
Journal:  Schizophr Bull       Date:  2009-02-04       Impact factor: 9.306

3.  Glucose abnormalities in the siblings of people with schizophrenia.

Authors:  Emilio Fernandez-Egea; Miguel Bernardo; Eduard Parellada; Azucena Justicia; Clemente Garcia-Rizo; Enric Esmatjes; Ignacio Conget; Brian Kirkpatrick
Journal:  Schizophr Res       Date:  2008-06-02       Impact factor: 4.939

Review 4.  Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications.

Authors:  Henry J Riordan; Paola Antonini; Michael F Murphy
Journal:  Am Health Drug Benefits       Date:  2011-09

Review 5.  Atypical antipsychotic-induced metabolic disturbances in the elderly.

Authors:  Melanie Dawn Guenette; Araba Chintoh; Gary Remington; Margaret Hahn
Journal:  Drugs Aging       Date:  2014-03       Impact factor: 3.923

Review 6.  Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders--a systematic review and meta-analysis.

Authors:  Alex J Mitchell; Davy Vancampfort; Kim Sweers; Ruud van Winkel; Weiping Yu; Marc De Hert
Journal:  Schizophr Bull       Date:  2011-12-29       Impact factor: 9.306

7.  Pathway-wide association study identifies five shared pathways associated with schizophrenia in three ancestral distinct populations.

Authors:  C Liu; C A Bousman; C Pantelis; E Skafidas; D Zhang; W Yue; I P Everall
Journal:  Transl Psychiatry       Date:  2017-02-21       Impact factor: 6.222

Review 8.  Brain insulin dysregulation: implication for neurological and neuropsychiatric disorders.

Authors:  Rasoul Ghasemi; Leila Dargahi; Ali Haeri; Maryam Moosavi; Zahurin Mohamed; Abolhassan Ahmadiani
Journal:  Mol Neurobiol       Date:  2013-01-20       Impact factor: 5.590

9.  Metabolic profile of antipsychotic-naive individuals with non-affective psychosis.

Authors:  Emilio Fernandez-Egea; Miguel Bernardo; Thomas Donner; Ignacio Conget; Eduard Parellada; Azucena Justicia; Enric Esmatjes; Clemente Garcia-Rizo; Brian Kirkpatrick
Journal:  Br J Psychiatry       Date:  2009-05       Impact factor: 9.319

10.  Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem.

Authors:  Dwight Dickinson; Philip D Harvey
Journal:  Schizophr Bull       Date:  2008-08-09       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.